Abeona Posts $13.5M in Q3 Revenue, Topping Q2's $11.4M
ABEO is trading near its 52-week low of $3.91 (2.6% above the low).
Summary
Abeona reported third-quarter revenue of $13.5 million, up from $11.4 million in Q2 — roughly 18% sequential growth on the ZEVASKYN launch, against a Q3 revenue estimate of 14.82M USD. That extends the ramp reported in August, when Q2 revenue rose 31% sequentially from $8.7 million. The company entered the quarter with $146.8 million in cash as of the Q2 filing, and today it also disclosed the ABO-801 acquisition from Ellodi for $20 million in stock plus up to $60 million in milestones; ABO-801 is the Phase 3-ready APT-1011, and the company entered into an agreement for a $30 million private placement. Third-quarter research and development expenses were $3.7 million, and the quarter's profit beat expectations on treatment network expansion. Revenue is still small against a roughly $238 million market cap, but the stock sits near its 52-week low of $3.91, so a clean sequential beat on the launch curve matters for sentiment. Watch the full 10-Q for gross-to-net, patient counts and any repeat of the manufacturing batch rejection flagged last quarter.
At the time of this announcement, ABEO was trading at $4.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $238.5M. The 52-week trading range was $3.91 to $7.65. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.